At the news
? BULLISHIMPACT 7/10 8-K filed Jul 13, 2026 at 09:10 ET
Esperion Therapeutics completed its acquisition by ArchiMed (via Essence Parent Inc.) on July 13, 2026, for $3.16 per share in cash plus one contingent value right (CVR) per share, representing up to $100M in aggregate milestone payments. The merger triggers delisting from Nasdaq, a change of control, replacement of the board, and termination of the prior credit agreement with new debt financing from BioPharma Credit.
- Merger completed on July 13, 2026; each share converted into $3.16 cash plus one CVR
- Total cash consideration approximately $1.1 billion, funded by equity and debt from BioPharma Credit
- CVRs entitle holders to up to $100M aggregate contingent payments tied to U.S. net sales milestones for NEXLETOL/NEXLIZET (bempedoic acid) and ENBUMYST (bumetanide)
- Common stock to be delisted from Nasdaq; Form 15 to be filed to suspend SEC reporting obligations
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access